Use of growth hormone and insulin-like growth factor 1 for treatment of tissue wasting in catabolic conditions

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Trauma, surgery, burn injury, sepsis, prolonged bed rest, cancer, and AIDS are examples of catabolic states that can lead to a significant loss of lean body tissues and skeletal muscle. The physiologic stresses associated with these catabolic conditions can impair immune function, alter drug response, and delay the recovery process. Although enhanced nutritional supplementation is a mainstay for treating tissue wasting in these conditions, it is of limited effectiveness in reversing skeletal muscle protein loss or enhancing anabolism in lean body tissues. The use of anabolic hormones such as growth hormone (GH) or Insulin-like growth factor 1 (IGF-1) to limit lean body wasting and preserve muscle mass in these conditions has been widely investigated. This article was designed to give pharmacists and patient care professionals an overview of recent literature involving anabolic hormone treatment of tissue wasting. The use of these agents in the clinical setting may undergo significant expansion in the near future.

Original languageEnglish (US)
Pages (from-to)163-168
Number of pages6
JournalHospital Pharmacy
Volume36
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Somatomedins
Growth Hormone
Tissue
Muscle
Skeletal Muscle
Hormones
Bed Rest
Muscle Proteins
Wounds and Injuries
Therapeutics
Pharmacists
Surgery
Sepsis
Patient Care
Acquired Immunodeficiency Syndrome
Recovery
Muscles
Pharmaceutical Preparations
Neoplasms

Keywords

  • Anabolic hormones
  • Cachexia
  • Catabolic illness
  • Growth hormone
  • Insulin-like growth factor 1

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{bd091b0ce42543b2800254a1ed695062,
title = "Use of growth hormone and insulin-like growth factor 1 for treatment of tissue wasting in catabolic conditions",
abstract = "Trauma, surgery, burn injury, sepsis, prolonged bed rest, cancer, and AIDS are examples of catabolic states that can lead to a significant loss of lean body tissues and skeletal muscle. The physiologic stresses associated with these catabolic conditions can impair immune function, alter drug response, and delay the recovery process. Although enhanced nutritional supplementation is a mainstay for treating tissue wasting in these conditions, it is of limited effectiveness in reversing skeletal muscle protein loss or enhancing anabolism in lean body tissues. The use of anabolic hormones such as growth hormone (GH) or Insulin-like growth factor 1 (IGF-1) to limit lean body wasting and preserve muscle mass in these conditions has been widely investigated. This article was designed to give pharmacists and patient care professionals an overview of recent literature involving anabolic hormone treatment of tissue wasting. The use of these agents in the clinical setting may undergo significant expansion in the near future.",
keywords = "Anabolic hormones, Cachexia, Catabolic illness, Growth hormone, Insulin-like growth factor 1",
author = "Martin Zdanowicz",
year = "2001",
language = "English (US)",
volume = "36",
pages = "163--168",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "2",

}

TY - JOUR

T1 - Use of growth hormone and insulin-like growth factor 1 for treatment of tissue wasting in catabolic conditions

AU - Zdanowicz, Martin

PY - 2001

Y1 - 2001

N2 - Trauma, surgery, burn injury, sepsis, prolonged bed rest, cancer, and AIDS are examples of catabolic states that can lead to a significant loss of lean body tissues and skeletal muscle. The physiologic stresses associated with these catabolic conditions can impair immune function, alter drug response, and delay the recovery process. Although enhanced nutritional supplementation is a mainstay for treating tissue wasting in these conditions, it is of limited effectiveness in reversing skeletal muscle protein loss or enhancing anabolism in lean body tissues. The use of anabolic hormones such as growth hormone (GH) or Insulin-like growth factor 1 (IGF-1) to limit lean body wasting and preserve muscle mass in these conditions has been widely investigated. This article was designed to give pharmacists and patient care professionals an overview of recent literature involving anabolic hormone treatment of tissue wasting. The use of these agents in the clinical setting may undergo significant expansion in the near future.

AB - Trauma, surgery, burn injury, sepsis, prolonged bed rest, cancer, and AIDS are examples of catabolic states that can lead to a significant loss of lean body tissues and skeletal muscle. The physiologic stresses associated with these catabolic conditions can impair immune function, alter drug response, and delay the recovery process. Although enhanced nutritional supplementation is a mainstay for treating tissue wasting in these conditions, it is of limited effectiveness in reversing skeletal muscle protein loss or enhancing anabolism in lean body tissues. The use of anabolic hormones such as growth hormone (GH) or Insulin-like growth factor 1 (IGF-1) to limit lean body wasting and preserve muscle mass in these conditions has been widely investigated. This article was designed to give pharmacists and patient care professionals an overview of recent literature involving anabolic hormone treatment of tissue wasting. The use of these agents in the clinical setting may undergo significant expansion in the near future.

KW - Anabolic hormones

KW - Cachexia

KW - Catabolic illness

KW - Growth hormone

KW - Insulin-like growth factor 1

UR - http://www.scopus.com/inward/record.url?scp=0035115743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035115743&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035115743

VL - 36

SP - 163

EP - 168

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 2

ER -